logindetails
Well-Known Member
- Messages
- 297
- Location
- Swansea UK
- Type of diabetes
- Type 1
- Treatment type
- Insulin
- Dislikes
- Neuropathy :-(
I had a letter yesterday asking me if I'd be prepared to put myself forward for a clinical trial, INSTRIDE 1 (or INSTRIDE 2 for type 2's) investigating whether a generic long acting insulin produced by Mylan is as effective as Lantus.
I don't know if there is any payment for participating in the trial but as it would require me to swap my current insulins (Tresiba & NovoRapid) for Mylan's insulin glargine or Lantus & insulin lispro for meals, for up to 66 weeks, I doubt I will be putting myself forward.
An interesting quote from the letter:
"If the investigational medication is approved, it could be a more affordable treatment option, becoming more widely available and benefiting more people worldwide."
I applaud that (if approved) it will make the treatment of diabetes more affordable to many people worldwide. However I wonder if in the UK it will have the effect of restricting diabetics to a cheap generic insulin rather than one that is more suitable for them as doctors come under pressure to reduce NHS costs?
I don't know if there is any payment for participating in the trial but as it would require me to swap my current insulins (Tresiba & NovoRapid) for Mylan's insulin glargine or Lantus & insulin lispro for meals, for up to 66 weeks, I doubt I will be putting myself forward.
An interesting quote from the letter:
"If the investigational medication is approved, it could be a more affordable treatment option, becoming more widely available and benefiting more people worldwide."
I applaud that (if approved) it will make the treatment of diabetes more affordable to many people worldwide. However I wonder if in the UK it will have the effect of restricting diabetics to a cheap generic insulin rather than one that is more suitable for them as doctors come under pressure to reduce NHS costs?